Review of clinical studies and first clinical experiences with a commercially available cone-beam breast CT in Europe

Wienbeck, Susanne; Lotz, Joachim; Fischer, Uwe

doi:10.1016/j.clinimag.2016.11.011

Cited by 54 publications

(37 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the positioning of the patient has to be carefully done by the technician to obtain the optimal coverage and to include as much external glandular component as possible. Limited coverage of axilla and axillary tail compared with mammography is a known limitation of B-CT. 14,26 However, enlarged lymph nodes on otherwise normal mammograms are rarely malignant and clinically significant, and their noninclusion in B-CT images can be considered of negligible clinical value. A comprehensive evaluation of the breast glandular tissue needs to be guaranteed also in women with glandular extension in the axillary tail area by integrating B-CT images with a sonographic evaluation.…”

Section: Discussionmentioning

confidence: 99%

Dedicated Breast Computed Tomography With a Photon-Counting Detector

et al. 2019

View full text Add to dashboard Cite

OBJECTIVES: The purpose of this work is to present the data obtained from the first clinical in vivo application of a new dedicated spiral breast computed tomography (B-CT) equipped with a photon-counting detector. MATERIALS AND METHODS: The institutional review board approved this retrospective study. Twelve women referred for breast cancer screening were included and underwent bilateral spiral B-CT acquired in prone position. Additional sonography was performed in case of dense breast tissue or any B-CT findings. In 3 women, previous mammography was available for comparison. Soft tissue (ST) and high-resolution (HR) images were reconstructed. Two independent radiologists performed separately the readout for subjective image quality and for imaging findings detection. Objective image quality evaluation was performed in consensus and included spatial resolution, contrast resolution, signal-to-noise ratio (SNR), and contrast-to-noise ratio. All women were asked to report about positioning comfort and overall comfort during data acquisition. RESULTS: The major pectoral muscle was included in 15 breast CT scans (62.5%); glandular component was partially missing in 2 (8.3%) of the 24 scanned breasts. A thin "ring artifact" was present in all scans but had no influence on image interpretations; no other artifacts were present. Subjective image quality assessment showed excellent agreement between the 2 readers (= 1). Three masses were depicted in B-CT and were confirmed as simple cysts in sonography. Additional 5 simple cysts and 2 solid benign lesions were identified only in sonography. A total of 12 calcifications were depicted with a median size of 1.1 mm (interquartile range, 0.7-1.7 mm) on HR and 1.4 mm (interquartile range, 1.1-1.8 mm) on ST images. Median SNRgl, SNRfat, and contrast-to-noise ratio were significantly higher in ST than in HR reconstructions (each, P < 0.001). A mild discomfort due to positioning of the rib cage on the table was reported by 2 women (16.7%); otherwise, no discomfort was reported. CONCLUSIONS: The new dedicated B-CT equipped with a photon-counting detector provides high-quality images with potential for screening of breast cancer along with minor patient discomfort.

show abstract

Section: Discussionmentioning

confidence: 99%

Dedicated Breast Computed Tomography With a Photon-Counting Detector

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Early diagnosis of lung adenocarcinoma is challenging. Traditional imaging examinations such as CT and MRI are based on changes in tissue morphology [15][16][17][18] , and often lack sufficient specificity to fully predict a tumor's behavior [19][20][21] . Therefore, it is essential to find tumor-specific molecules and establish reliable imaging methods for accurate diagnosis.…”

Section: Discussionmentioning

confidence: 99%

SP70-Targeted Imaging for the Early Detection of Lung Adenocarcinoma

Zhang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

NJ001 is a monoclonal antibody that can specifically recognize the SP70 antigen on lung adenocarcinoma cells. The goal of this study was to explore its utility in targeted imaging. Subcutaneous xenograft and orthotopic lung tumor implantation BALB/c mouse models were established. Near-infrared fluorescent CF750-labeled NJ001 was injected into two tumor mouse models. Mice that received orthotopic lung tumor implantation were also injected with NJ001-conjugated nanomagnetic beads intravenously, and then underwent micro-CT scanning. Meanwhile, mice with lung tumor were intravenously injected with normal saline and bare nanomagnetic beads as a control. Fluorescence could be monitored in the mice detected by anti-SP70 fluorescence imaging, which was consistent with tumor burden. Signal intensities detected with SP70-targeted micro-CT scans were greater than those in control mice. More importantly, orthotopic tumor lesions could be found on the fourth week with SP70-targeted imaging, which was 2 weeks earlier than detection in the control. Our results suggest that SP70 is a promising target for molecular imaging, and molecularly targeted imaging with an NJ001-labeled probe could be applied for the early detection of lung adenocarcinoma. Lung cancer is the leading cause of cancer-related death in humans 1,2. Approximately 1,590,000 people died from lung cancer in 2012 3. Five-year survival rates vary from 4-17%, depending on stage and regional differences 4. Late diagnosis makes treatment options challenging, but early detection could significantly reduce mortality in lung cancer patients 5-7. Different imaging modalities can be used for lung cancer detection, such as computed tomography (CT), magnetic resonance imaging (MRI), and 18 F-fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT). However, they lack sufficient specificity for the early detection of tumors 8. Molecularly targeted tumor imaging with a specific monoclonal antibody is superior to conventional nonspecific imaging technologies 9,10. Nevertheless, there are few reports on molecularly targeted imaging for the detection of lung cancer, because of the lack of molecular targets with high specificity for lung cancer. SP70 protein is a novel tumor marker of non-small-cell lung cancer (NSCLC), especially lung adenocarcinoma 11. SP70's monoclonal antibody NJ001 could specifically recognize and react to lung adenocarcinoma cells 12. In this study, we aimed to demonstrate the feasibility of SP70-targeted imaging with NJ001-conjugated nanomagnetic beads (immuno-nanomagnetic beads) in lung adenocarcinoma and the potential for its use in real-time monitoring and early detection. Results Bioluminescence intensity correlated with cell number. Both SPC-A1-luc and U87-luc cells were diluted by a serial 2-fold dilution method, and then luciferase activity was measured. Bioluminescence intensity was highly correlated with the total number of cells (R 2 > 0.9900) for both cell lines (Fig. S1). Furthermore, the average luciferase activity va...

show abstract

“…CBBCT examinations were performed using a dedicated flat-panel breast-CT (Koning Breast CT, CBCT 1000; Koning Corporation, West Henrietta, NY, USA). CBBCT imaging was done in a standard manner [13] , [15] . After initial NC-CBBCT, 90 mL non-ionic contrast media (Iopromide, Ultravist® 300, Bayer-Schering, Berlin, Germany) were intravenously injected, followed by a 30 mL saline solution chaser.…”

Section: Methodsmentioning

confidence: 99%

“…Recent advances in breast imaging could further promote the discrimination of breast cancer subtypes. Cone-beam breast-CT (CBBCT) is a novel breast imaging technique, utilizing a dedicated flat-panel CT for acquisition of true breast 3D images [12] , [13] . Although it has been shown that lesion intensity on non-contrast (NC) CBBCT did not correlate with breast cancer receptor status or histopathological diagnosis, there is no literature on the added benefit of iodinated contrast media in this emerging imaging modality [14] .…”

Section: Introductionmentioning

confidence: 99%

Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes

Uhlig

Fischer²,

Fintel

et al. 2017

Translational Oncology

Self Cite

View full text Add to dashboard Cite

PURPOSE: To evaluate whether contrast enhancement on cone-beam breast-CT (CBBCT) could aid in discrimination of breast cancer subtypes and receptor status. METHODS: This study included female patients age >40 years with malignant breast lesions identified on contrast-enhanced CBBCT. Contrast enhancement of malignant breast lesions was standardized to breast fat tissue contrast enhancement. All breast lesions were approved via image-guided biopsy or surgery. Immunohistochemical staining was conducted for expression of estrogen (ER), progesterone (PR), human epidermal growth factor receptor-2 (HER2) and Ki-67 index. Contrast enhancement of breast lesions was correlated with immunohistochemical breast cancer subtypes (Luminal A, Luminal B, HER2 positive, triple negative), receptor status and Ki-67 expression. RESULTS: Highest contrast enhancement was seen for Luminal A lesions (93.6 HU) compared to Luminal B lesions (47.6 HU, P = .002), HER2 positive lesions (83.5 HU, P = .359) and triple negative lesions (45.3 HU, P = .005). Contrast enhancement of HER2 positive lesions was higher than Luminal B lesions (P = .044) and triple negative lesions (P = .039). No significant difference was evident between Luminal B and triple negative lesions (P = .439). Lesions with high Ki-67 index showed lower contrast enhancement than those with low Ki-67 index (P = .0043). ER, PR and HER2 positive lesions demonstrated higher contrast enhancement than their receptor negative counterparts, although differences did not reach statistical significance (P = .1714; P = .3603; P = .2166). CONCLUSIONS: Contrast enhancement of malignant breast lesions on CBBCT correlates with immunohistochemical subtype and proliferative potential. Thereby, CBBCT might aid in selecting individualized treatment strategies for breast cancer patients based on pre-operative imaging.

show abstract

Review of clinical studies and first clinical experiences with a commercially available cone-beam breast CT in Europe

Cited by 54 publications

References 35 publications

Dedicated Breast Computed Tomography With a Photon-Counting Detector

Dedicated Breast Computed Tomography With a Photon-Counting Detector

SP70-Targeted Imaging for the Early Detection of Lung Adenocarcinoma

Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes

Contact Info

Product

Resources

About